Review
Oncology
V. Formica, C. Morelli, A. Patrikidou, KK. Shiu, A. Nardecchia, J. Lucchetti, M. Roselli, HT. Arkenau
Summary: PD-L1 positive patients derive significant survival benefit from immune checkpoint inhibitors in gastro-oesophageal junction/gastric cancer, with other predictors needed for further refining patient selection.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Gengwei Huo, Wenjie Liu, Peng Chen
Summary: This meta-analysis evaluates the efficacy of PD-1/PD-L1 inhibitors in advanced gastric cancer and gastroesophageal junction cancer patients. The results show that PD-1/PD-L1 inhibitors have a significant effect on improving overall survival in these patients compared to chemotherapy, but no significant improvement is observed in progression-free survival. Additionally, age and sex can be used to predict the treatment efficacy of PD-1/PD-L1 inhibitors in these patients.
Article
Pharmacology & Pharmacy
Li Chen, Ruihu Zhao, Hao Sun, Rong Huang, Hongming Pan, Yanjiao Zuo, Lele Zhang, Yingwei Xue, Xingrui Li, Hongjiang Song
Summary: This study aimed to investigate the prognostic value of the gastric immune prognostic index (GIPI) in gastric cancer patients treated with PD-1/PD-L1 inhibitors. The results showed that patients with GIPI intermediate/poor had shorter progression-free survival (PFS) and overall survival (OS) compared to those with GIPI good, especially in subgroups of patients receiving immune checkpoint inhibitor (ICI) treatment and patients with PD-1/PD-L1 positive status. Therefore, GIPI may be useful for identifying gastric cancer patients who are unlikely to benefit from PD-1/PD-L1 inhibitor treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Xianzhe Yu, Xiaoqian Zhai, Juan Wu, Qingbo Feng, Chenggong Hu, Lingling Zhu, Qinghua Zhou
Summary: Gastric cancer is a global health problem, and traditional therapies have limited efficacy. Immunotherapy using checkpoint inhibitors, particularly therapeutic antibodies targeting the PD-1/PD-L1 pathway, has made substantial breakthroughs in the treatment of gastric cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Review
Immunology
Muhammad Khan, Kunpeng Du, Meiling Ai, Baiyao Wang, Jie Lin, Anbang Ren, Chengcong Chen, Zhong Huang, Wenze Qiu, Yawei Yuan, Yunhong Tian
Summary: This study systematically analyzed the biomarker value of PD-L1 expression in predicting the efficacy of PD-1/PD-L1 checkpoint inhibitors in mTNBC patients. The results showed that PD-L1+ patients had significantly higher objective response rate, 1-year progression-free survival, and 2-year overall survival compared to PD-L1- patients. Subgroup analysis indicated that PD-L1 expression can successfully predict tumor response and 2-year overall survival benefit in mTNBC patients regardless of the type of investigating agent, line of treatment administration, and to some extent the type of treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Kabsoo Shin, Joori Kim, Se Jun Park, Myung Ah Lee, Jae Myung Park, Myung-Gyu Choi, Donghoon Kang, Kyo Young Song, Han Hong Lee, Ho Seok Seo, Sung Hak Lee, Bohyun Kim, Okran Kim, Juyeon Park, Nahyeon Kang, In-Ho Kim
Summary: The study investigated the prognostic significance of soluble PD-L1 (sPD-L1) and exosomal PD-L1 (exoPD-L1) in patients with gastric cancer receiving chemotherapy. It was found that low levels of sPD-L1 and exoPD-L1 were associated with better overall survival and progression-free survival. Pretreatment sPD-L1 could be used as an independent prognostic factor for overall survival, while exoPD-L1 may reflect the immunosuppressive state of patients.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Karen Mulder, Howard Lim, Deepti Ravi, Shahida Ahmed, Bryan Brunet, Janine Davies, Corinne Doll, Dorie-Anna Dueck, Vallerie Gordon, Pamela Hebbard, Christina A. Kim, Duc Le, Richard Lee-Ying, John Paul McGhie, Jason Park, Daniel J. Renouf, Devin Schellenberg, Ralph P. W. Wong, Adnan Zaidi, Shahid Ahmed
Summary: Immunotherapy is increasingly recognized as playing an important role in the treatment of gastro-esophageal cancer, with experts from the Western Canadian Gastrointestinal Cancer Consensus Conference giving high attention to its role.
Article
Oncology
Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio
Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Yinan Yu, Xueying Jin, Xiaoling Zhu, Yan Xu, Wei Si, Jianguo Zhao
Summary: Through meta-analysis, the study found that PD-1/PD-L1 immune checkpoint inhibitors combined with chemotherapy can significantly improve the progression-free survival of patients with metastatic triple negative breast cancer, but only significantly improve the overall survival in PD-L1 positive population. In addition, the incidence of immune-related adverse events is significantly higher in the ICIs group compared to chemotherapy, which needs to be taken seriously.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Pasquale Pisapia, Antonino Iaccarino, Caterina De Luca, Gennaro Acanfora, Claudio Bellevicine, Roberto Bianco, Bruno Daniele, Luisa Ciampi, Marco De Felice, Teresa Fabozzi, Luigi Formisano, Pasqualina Giordano, Cesare Gridelli, Giovanni Pietro Ianniello, Annamaria Libroia, Paolo Maione, Mariantonia Nacchio, Fabio Pagni, Giovanna Palmieri, Francesco Pepe, Gianluca Russo, Maria Salatiello, Antonio Santaniello, Rachele Scamarcio, Davide Seminati, Michele Troia, Giancarlo Troncone, Elena Vigliar, Umberto Malapelle
Summary: This study fills the information gap regarding the role of ICIs in NSCLC patients with other driver mutations and provides a molecular landscape of clinically relevant oncogenic drivers in PD-L1 positive NSCLC patients. The results demonstrate that some patients with a PD-L1 tumor proportion score of 50% or higher and concomitant gene alterations may benefit from ICIs treatment, even in the presence of a KRAS gene alteration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Li Chen, Hao Sun, Ruihu Zhao, Rong Huang, Hongming Pan, Yanjiao Zuo, Lele Zhang, Yingwei Xue, Xingrui Li, Hongjiang Song
Summary: The study investigated the correlation between the controlling nutritional status (CONUT) and prognosis in gastric cancer patients receiving immune checkpoint inhibitor (ICI) treatment. The results showed that high CONUT score was associated with poorer progression-free survival (PFS) and overall survival (OS). A nomogram was developed to predict the probability of PFS and OS. CONUT may be useful in identifying gastric cancer patients who are unlikely to benefit from ICI treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Philip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret McGrath, Susan Arnold, Jermaine Coward, Samuel Fourie, Andriy Kurochkin, Daniel R. Malan, Andrew Mant, Vinay Sharma, Hong Shue, Andrea Tazbirkova, Miguel-Angel Berciano-Guerrero, Chaiyut Charoentum, Stephane Dalle, Arunee Dechaphunkul, Oleksandr Dudnichenko, Piotr Koralewski, Iwona Lugowska, Henri Montaudie, Eva Munoz-Couselo, Virote Sriuranpong, James Oliviero, Jayesh Desai
Summary: Cosibelimab demonstrated clinically meaningful objective response rate and duration of response in patients with metastatic CSCC, with a manageable safety profile.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Xiao Zhang, Zhengyang Yang, Yongbo An, Yishan Liu, Qi Wei, Fengming Xu, Hongwei Yao, Zhongtao Zhang
Summary: This study conducted a meta-analysis on the clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer (mCRC). The results showed encouraging clinical benefits, particularly in terms of response rate. However, further multicenter prospective studies are still needed.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Birgid Schoemig-Markiefka, Jana Eschbach, Andreas H. Scheel, Aylin Pamuk, Josef Rueschoff, Thomas Zander, Reinhard Buettner, Wolfgang Schroeder, Christiane J. Bruns, Heike Loeser, Hakan Alakus, Alexander Quaas
Summary: This study optimized PD-L1 assessment in gastric cancer using endoscopically available tissue and found that CPS values from four surface biopsies can accurately reflect the PD-L1 status of the entire tumor. Preoperative biopsies showed lower sensitivity compared to tissue microarrays (TMAs).
Article
Gastroenterology & Hepatology
Patrizia Ferroni, Vincenzo Formica, David Della-Morte, Jessica Lucchetti, Antonella Spila, Roberta D'Alessandro, Silvia Riondino, Fiorella Guadagni, Mario Roselli
WORLD JOURNAL OF GASTROENTEROLOGY
(2016)
Article
Gastroenterology & Hepatology
Fiorella Guadagni, Silvia Riondino, Vincenzo Formica, Girolamo Del Monte, Anna Maria Morelli, Jessica Lucchetti, Antonella Spila, Roberta D'Alessandro, David Della-Morte, Patrizia Ferroni, Mario Roselli
WORLD JOURNAL OF GASTROENTEROLOGY
(2017)
Article
Oncology
Francesca Battaglin, Marta Schirripa, Federica Buggin, Filippo Pietrantonio, Federica Morano, Giorgia Boscolo, Giuseppe Tonini, Eufemia Stefania Lutrino, Jessica Lucchetti, Lisa Salvatore, Alessandro Passardi, Chiara Cremolini, Ermenegildo Arnoldi, Mario Scartozzi, Nicoletta Pella, Luca Boni, Francesca Bergamo, Vittorina Zagonel, Fotios Loupakis, Sara Lonardi
Article
Oncology
Vincenzo Formica, Michaela Benassi, Giovanna Del Vecchio Blanco, Elena Doldo, Laura Martano, Ilaria Portarena, Antonella Nardecchia, Jessica Lucchetti, Cristina Morelli, Emilia Giudice, Piero Rossi, Alessandro Anselmo, Pierpaolo Sileri, Giuseppe Sica, Augusto Orlandi, Riccardo Santoni, Mario Roselli
Article
Oncology
Vincenzo Formica, Jessica Luccchetti, David Cunningham, Elizabeth C. Smyth, Patrizia Ferroni, Antonella Nardecchia, Manfredi Tesauro, Vittore Cereda, Fiorella Guadagni, Mario Roselli
Article
Oncology
Jessica Lucchetti, Vincenzo Formica, Greta Giuliano, Deborah Coletta, Letizia Gargano, Daniele Morosetti, Pierpaolo Sileri, Giampiero Palmieri, Mario Roselli
ANTICANCER RESEARCH
(2018)
Review
Oncology
V. Formica, C. Morelli, A. Patrikidou, KK. Shiu, A. Nardecchia, J. Lucchetti, M. Roselli, HT. Arkenau
Summary: PD-L1 positive patients derive significant survival benefit from immune checkpoint inhibitors in gastro-oesophageal junction/gastric cancer, with other predictors needed for further refining patient selection.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Vincenzo Formica, Jessica Lucchetti, Elena Doldo, Silvia Riondino, Cristina Morelli, Renato Argiro, Nicola Renzi, Daniele Nitti, Antonella Nardecchia, Emanuela Dell'Aquila, Patrizia Ferroni, Fiorella Guadagni, Giampiero Palmieri, Augusto Orlandi, Mario Roselli
Summary: This study demonstrates that mutational analysis through plasma can better predict survival outcomes for colorectal cancer patients, compared to relying solely on tumor tissue analysis. Plasma mutations further refine prognosis and can help guide clinical management.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Health Care Sciences & Services
Vincenzo Formica, Antonella Nardecchia, Cristina Morelli, Jessica Lucchetti, Greta Giuliano, Nicola Renzi, Chiara Gallo, Rachela Pellegrino, Valentina Massimiliani, Cristiano Serci, Anna Russo, Anna Patrikidou, Hendrik-Tobias Arkenau, Luigi Maiorino, Manfredi Tesauro, Mario Roselli
Summary: High BMI, young age, and male sex were found to be protective factors against HRQoL deterioration in metastatic colorectal cancer patients. In centers where HRQoL assessment is not routine, such assessment should be considered for mCRC patients who meet the risk criteria outlined in the proposed nomogram (i.e., females over 65 years old with BMI < 23).
ANNALS OF PALLIATIVE MEDICINE
(2021)